Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
10Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Insmed Incorporated (INSM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
2Distinct source URLs
8High confidence
0.751Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Insmed Incorporated Suppliers
Ticker
Name
Confidence
Evidence
ESTEVE-QU-MICA-S-A
ESTEVE-QU-MICA-S-A
92%
In September 2024, we entered into a commercial manufacturing and supply agreement with Esteve Química, S.A. (Esteve) for the manufacture and supply of brensocatib's active pharmaceutical ingredient.
PARI
PARI
92%
We have a commercialization agreement with PARI, the manufacturer of our drug delivery nebulizer for ARIKAYCE, to address our commercial supply needs (the Commercialization Agreement).
PATHEON-UK-LIMITED
PATHEON-UK-LIMITED
92%
The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated long-term commercial needs.
RESILIENCE-BIOTECHNOLOGIES-INC
RESILIENCE-BIOTECHNOLOGIES-INC
92%
ARIKAYCE is manufactured currently by Resilience Biotechnologies Inc. (Resilience) (formerly Therapure Biopharma Inc.) in Canada at a 200 kilogram (kg) scale.
evelopment industry has a history of intellectual property litigation, and we may become involved in costly intellectual property disputes, which may delay or impair our product development efforts o…
Reciprocal relationship from ORANY graph: Reciprocal relationship from INSM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INSM graph: Reciprocal relationship from ORAN…
Reciprocal relationship from SLDB graph: Reciprocal relationship from INSM graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from INSM graph: Reciprocal relationship from SLDB g…
Insmed Incorporated Customers
Ticker
Name
Confidence
Evidence
CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC
CYSTIC-FIBROSIS-FOUNDATION-THERAPEUTICS-INC
90%
In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) whereby we received $1.7 million and $2.2 million in research funding for the d…
BIOPHARMA-CREDIT-PLC-BPCR-LIMITED
BIOPHARMA-CREDIT-PLC-BPCR-LIMITED
62%
mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t…
BRIDGEWATER-BIOTECH-CENTER-LLC
BRIDGEWATER-BIOTECH-CENTER-LLC
62%
mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t…
INITIAL-TERM-RESILIENCE-BIOTECHNOLOGIES-INC
INITIAL-TERM-RESILIENCE-BIOTECHNOLOGIES-INC
62%
. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the …
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t…
PARI-PHARMA-GMBH
PARI-PHARMA-GMBH
62%
rowth; • our inability to successfully integrate our acquisitions and appropriately manage the amount of management’s time and attention devoted to integration activities; • risks that our acquired t…
SVB-LEERINK-LLC
SVB-LEERINK-LLC
62%
mercial activities in p reparation for a launch of brensocatib for patients with bronchiectasis. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, t…
THERAPURE-BIOPHARMA-INC
THERAPURE-BIOPHARMA-INC
62%
. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the …
TPIP-PATHEON-UK-LIMITED
TPIP-PATHEON-UK-LIMITED
62%
. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days’ written notice, (ii) any project addendum in the event of the …
VERTUIS-BIO-INC
VERTUIS-BIO-INC
62%
become entitled to receive contingent payments up to an aggregate of $ 326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalt…
Insmed Incorporated Debt Obligations
Instrument
Description
Confidence
Evidence
INSM-DEBT-10301
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
INSM-DEBT
Debt stack $552.2M
90%
Market cache reports total debt of $552.2M.
Insmed Incorporated Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Insmed Incorporated.
Insmed Incorporated Ownership
Holder
Name
Confidence
Evidence
INSM-OWNER-JPMORGAN-CHASE-CO
JPMORGAN CHASE & CO
90%
13F overlay lists JPMORGAN CHASE & CO as top holder; 675 tracked holders.
